Patents by Inventor David P. Andrew

David P. Andrew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • WNT-regulated cytokine-like polypeptide and nucleic acids encoding same
    Patent number: 7566536
    Abstract: The present invention provides novel polypeptides, termed FCTRX polypeptides, as well as polynucleotides encoding FCTRX polypeptides and antibodies that immunospecifically bind to an FCTRX or a derivative, variant, mutant, or fragment of an FCTRX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the FCTRX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.
    Type: Grant
    Filed: July 7, 2003
    Date of Patent: July 28, 2009
    Assignees: CuraGen Corporation, Genentech, Inc.
    Inventors: David P. Andrew, David A. Lewin, Diane Pennica, Luca Rastelli, Bruce Tallion
  • Methods of treating inflammatory disease using antibodies which bind GPR-9-6
    Patent number: 7485301
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: February 3, 2009
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath
  • Anti-TECK antibodies and methods of use therefor
    Patent number: 7381412
    Abstract: The invention relates to antibodies or antigen-binding fragments thereof which binds the chemokine mammalian TECK and inhibit binding of the chemokine to mammalian GPR-9-6. The invention also relates to host cells that produce such antibodies or antigen-binding fragments, kits comprising such antibodies or antigen-binding fragments and methods of use for such antibodies and antigen-binding fragments.
    Type: Grant
    Filed: April 19, 2005
    Date of Patent: June 3, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath
  • Anti-CCR4 antibodies and methods of use therefor
    Patent number: 7138117
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 4 (CCR4) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR4 with a ligand thereof, and to use of the antibodies and fragments in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: November 21, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Lijun Wu, Nancy Ruffing-Graham, David P. Andrew
  • Methods of inhibiting GPR-9-6 function
    Patent number: 6936248
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: August 30, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brain A. Zabel, Paul D. Ponath
  • Methods of identifying agents which inhibit GPR-9-6
    Patent number: 6884574
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: April 26, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath
  • Methods of identifying agents which bind GPR-9-6
    Patent number: 6689570
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: September 13, 2001
    Date of Patent: February 10, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath
  • Novel proteins and nucleic acids encoding same
    Publication number: 20030082757
    Abstract: Disclosed herein are acid sequences which encode polypeptides. Also disclosed are nucleic acid sequences, and antibodies which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses thereapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
    Type: Application
    Filed: February 8, 2001
    Publication date: May 1, 2003
    Inventors: Raymond J. Taupier, Catherine E. Burgess, Muralidhara Padigaru, Velizar T. Tchernev, Vishnu S. Mishra, Stacie J. Casman, Robert A. Ballinger, Corine A.M. Vernet, Li Li, Kimberly A. Spytek, David P. Andrew, Peter S. Mezes
  • Methods of identifying agents which inhibit GPR-9-6
    Publication number: 20030022238
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: September 28, 2001
    Publication date: January 30, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath
  • Methods of treating inflammatory disease using antibodies which bind GPR-9-6
    Publication number: 20020141991
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: October 23, 2001
    Publication date: October 3, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath
  • Methods of identifying agents which bind GPR-9-6
    Publication number: 20020119504
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: September 13, 2001
    Publication date: August 29, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath
  • Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
    Patent number: 6329159
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: March 11, 1999
    Date of Patent: December 11, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath